company background image
5242

Kopran BSE:524280 Stock Report

Last Price

₹227.30

Market Cap

₹11.6b

7D

1.8%

1Y

17.4%

Updated

19 May, 2022

Data

Company Financials
524280 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends2/6

524280 Stock Overview

Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally.

Kopran Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Kopran
Historical stock prices
Current Share Price₹227.30
52 Week High₹369.35
52 Week Low₹172.00
Beta0.93
1 Month Change-19.14%
3 Month Change-19.94%
1 Year Change17.41%
3 Year Change479.11%
5 Year Change167.26%
Change since IPO178.73%

Recent News & Updates

Shareholder Returns

524280IN PharmaceuticalsIN Market
7D1.8%3.1%1.7%
1Y17.4%-10.9%10.5%

Return vs Industry: 524280 exceeded the Indian Pharmaceuticals industry which returned -10.9% over the past year.

Return vs Market: 524280 exceeded the Indian Market which returned 10.5% over the past year.

Price Volatility

Is 524280's price volatile compared to industry and market?
524280 volatility
524280 Average Weekly Movement8.0%
Pharmaceuticals Industry Average Movement7.0%
Market Average Movement7.3%
10% most volatile stocks in IN Market10.0%
10% least volatile stocks in IN Market4.8%

Stable Share Price: 524280 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 524280's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1958348n/ahttps://www.kopran.com

Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers finished dosage forms, including tablets, capsules, dry powder, suspension, and injectable in various therapeutic areas comprising cardiovascular, antidiabetic, gastrointestinal, pain management, drug for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, and antipeptic ulcer and gut. It also provides active pharmaceutical ingredients in the categories of anti-hypertensive, macrolide, neuromodulator, sterile cephalosporins, carbapenems, anti-acne, anti-infective, urological, anti-thrombotic, anti-ulcerant, anti-depressant.

Kopran Fundamentals Summary

How do Kopran's earnings and revenue compare to its market cap?
524280 fundamental statistics
Market Cap₹11.61b
Earnings (TTM)₹585.63m
Revenue (TTM)₹4.75b

19.7x

P/E Ratio

2.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
524280 income statement (TTM)
Revenue₹4.75b
Cost of Revenue₹2.83b
Gross Profit₹1.92b
Other Expenses₹1.33b
Earnings₹585.63m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 27, 2022

Earnings per share (EPS)11.55
Gross Margin40.42%
Net Profit Margin12.34%
Debt/Equity Ratio32.6%

How did 524280 perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

11%

Payout Ratio

Valuation

Is Kopran undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


19.68x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: 524280 (₹227.3) is trading above our estimate of fair value (₹58.41)

Significantly Below Fair Value: 524280 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 524280 is good value based on its PE Ratio (19.7x) compared to the Indian Pharmaceuticals industry average (21.7x).

PE vs Market: 524280 is good value based on its PE Ratio (19.7x) compared to the Indian market (20.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 524280's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 524280 is overvalued based on its PB Ratio (4.4x) compared to the IN Pharmaceuticals industry average (2.6x).


Future Growth

How is Kopran forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


21.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kopran has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Kopran performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


24.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 524280 has high quality earnings.

Growing Profit Margin: 524280's current net profit margins (12.3%) are higher than last year (11.7%).


Past Earnings Growth Analysis

Earnings Trend: 524280's earnings have grown significantly by 24.5% per year over the past 5 years.

Accelerating Growth: 524280's earnings growth over the past year (14%) is below its 5-year average (24.5% per year).

Earnings vs Industry: 524280 earnings growth over the past year (14%) exceeded the Pharmaceuticals industry 12.5%.


Return on Equity

High ROE: 524280's Return on Equity (22.3%) is considered high.


Financial Health

How is Kopran's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 524280's short term assets (₹3.1B) exceed its short term liabilities (₹1.9B).

Long Term Liabilities: 524280's short term assets (₹3.1B) exceed its long term liabilities (₹337.5M).


Debt to Equity History and Analysis

Debt Level: 524280's net debt to equity ratio (29.5%) is considered satisfactory.

Reducing Debt: 524280's debt to equity ratio has reduced from 54.8% to 32.6% over the past 5 years.

Debt Coverage: 524280's debt is well covered by operating cash flow (37.4%).

Interest Coverage: 524280's interest payments on its debt are well covered by EBIT (23x coverage).


Balance Sheet


Dividend

What is Kopran current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


1.32%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 524280's dividend (1.32%) is higher than the bottom 25% of dividend payers in the Indian market (0.35%).

High Dividend: 524280's dividend (1.32%) is low compared to the top 25% of dividend payers in the Indian market (1.57%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 524280 has been paying a dividend for less than 10 years.

Growing Dividend: 524280 has only been paying a dividend for 2 years, and since then payments have not increased.


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (11.1%), 524280's dividend payments are thoroughly covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: 524280 is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

8.0yrs

Average management tenure


CEO

Kopran has no CEO, or we have no data on them.


Leadership Team

Experienced Management: 524280's management team is seasoned and experienced (8 years average tenure).


Board Members

Experienced Board: 524280's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.3%.


Top Shareholders

Company Information

Kopran Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Kopran Limited
  • Ticker: 524280
  • Exchange: BSE
  • Founded: 1958
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹11.611b
  • Shares outstanding: 50.71m
  • Website: https://www.kopran.com

Number of Employees


Location

  • Kopran Limited
  • Parijat House
  • 1076, Dr. E Moses Road
  • Mumbai
  • Maharashtra
  • 400018
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/19 00:00
End of Day Share Price2022/05/19 00:00
Earnings2021/12/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.